Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
Executive Summary
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
You may also be interested in...
Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said
Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said
Obesity Drugs May Be Covered Under Part D; CMS Invites Limits On Viagra
Drugs to treat "morbid obesity" may be covered by Medicare Part D plans despite the exclusion of "weight loss agents" from the program, CMS indicated in the final rules implementing the Medicare Rx benefit